P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome

P-2：铂类化疗和放疗结果的风险预测

基本信息

批准号：
8731333
负责人：
Xifeng Wu
金额：
$ 10.57万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-12 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8731333
关键词：
Acute Adopted Alcohols Algorithms Apoptosis Apoptotic Base Excision Repairs Biological Assay Biological Markers Blood specimen Body Weight decreased Cancer Patient Cell Cycle Checkpoint Cell Cycle Regulation Cells Characteristics Chest Cisplatin Classification Clinical Clinical Data Code Combined Modality Therapy DNA DNA Repair Data Development Dose Double Strand Break Repair Enrollment Environment Epidemiologic Studies Epidemiology Family Cancer History Frequencies Functional disorder Genes Genetic Genetic Markers Genetic Polymorphism Genetic Variation Genotype Goals Haplotypes Individual Inflammation Integration Host Factors Interview Machine Learning Malignant neoplasm of lung Measures Medical Medical History Metabolism Modality Modeling Molecular Molecular Epidemiology Non-Small-Cell Lung Carcinoma Normal tissue morphology Nucleic Acid Regulatory Sequences Nucleotide Excision Repair Outcome Oxidative Stress P-2 Participant Pathway interactions Patients Penetrance Performance Status Pharmaceutical Preparations Platinum Platinum Compounds Platinum adduct Predisposition Proteins Protocols documentation RNA Splicing Radiation Radiation Induced DNA Damage Radiation Toxicity Radiation therapy Recording of previous events Research Infrastructure Risk Risk Assessment Series Site Smoking Specimen Staging Subgroup Texas Therapeutic Toxic effect Treatment Efficacy Treatment outcome Trees Tumor Tissue Universities Variant analog base chemoradiation chemotherapy clinical efficacy clinically relevant cohort design drug metabolism epidemiologic data experience follow-up gene environment interaction high risk improved novel protein function repaired response telomere tissue repair tool tumor uptake

项目摘要

The overarching goal of this project is to determine host epidemiologic and genetic factors that will be predictive of efficacy and toxicity of platinum-based chemotherapy or combined with thoracic radiotherapy in NSCLC patients. We will construct a well-characterized cohort of 1,200 NSCLC patients (Stages III and IV - receiving first-line platinum-based chemotherapy ¿ definitive thoracic radiotherapy). This cohort will then be studied for epidemiologic, clinical and a large number of rationally selected germline polymorphisms to correlate with the clinical outcome to allow us to construct predictive risk models for clinical efficacy and toxicity. We estimate there will be ~ 600 patients treated by platinum-based chemotherapy alone, and 600 Stage III patients receiving platinum-based chemotherapy plus definitive thoracic radiotherapy. There are three specific aims: 1) we will identify novel genetic loci that predict efficacy and toxicity to platinum-based chemotherapy and radiotherapy in all 1,200 patients. We will adopt a pathway-based genotyping and analyzing approach to evaluate frequencies .of about 8,000 SNPs in genes involved in pathways relevant to platinum and radiation response. We will examine individual SNP main effects, haplotypes, and the cumulative effect of SNPs in modulating efficacy and toxicity. Our hypothesis is that specific genotypes that alter the metabolism or action of platinum agents or relevant to the genotoxic effects of radiotherapy may impact the efficacy and toxicity of patients to these therapies. 2) we will apply machine-learning tools to identify gene-gene and gene-environment interactions influencing NSCLC outcome. We will develop algorithms to identify subgroups with differing platinum or radiotherapy treatment efficacy or toxicity. Our hypothesis is that therapeutic response is modulated by common, low penetrance polymorphisms, and that these polymorphisms interact with each other and/or host factors in determining response to therapy. 3) we will construct predictive risk models for survival and toxicity by integrating clinical and epidemiologic data with the genetic data from this project,and additional information from other R01 studies devoted to these cohorts such as a series of phenotypic assays. We hypothesize that the addition of genetic markers to the standard clinical and epidemiologic variables will improve the prediction of survival and toxicity of the final risk assessment models. We will compare the prediction accuracy among all patients, patients receiving chemotherapy alone, and patients treated by combined modality. The risk models resulting from this project may permit clinicians to identify patients before the start of therapy who are most and least likely to benefit or to develop toxicity and will have immense clinical benefit in terms of planning chemotherapy and radiotherapy for individual patients.

该项目的总体目标是确定宿主流行病学和遗传因素预测基于铂的化学疗法的效率和毒性，或与胸部放射疗法结合 NSCLC患者。我们将构建一个由1,200名NSCLC患者组成的特征良好的队列（III和IV阶段 - 接受一线铂基化学疗法 - 确定的胸部放射疗法）。然后这个队列将是研究了流行病学，临床和大量合理选择的种系多态性与临床结果相关，使我们能够为临床效率和毒性。我们估计将仅通过基于铂的化学疗法治疗约600例患者，而600例 III期患者接受基于铂的化学疗法以及明确的胸部放射疗法。有三个具体目的：1）我们将确定预测基于铂金的效率和毒性的新型遗传局部所有1200例患者的化学疗法和放疗。我们将采用基于途径的基因分型和分析方法评估频率的方法。铂和辐射反应。我们将检查单个SNP的主要影响，单倍型和 SNP在调节有效性和毒性中的累积效应。我们的假设是特定的基因型这改变了铂剂的代谢或作用，或与与遗传毒性作用相关的作用放疗可能会影响患者对这些疗法的效率和毒性。 2）我们将申请识别基因基因和基因环境相互作用的机器学习工具会影响NSCLC 结果。我们将开发算法以鉴定具有分化铂或放射治疗的亚组效率或毒性。我们的假设是，治疗反应是由常见，低的调节外渗性多态性，这些多态性相互相互作用和/或宿主确定对治疗反应的因素。 3）我们将构建生存的预测风险模型和通过将临床和流行病学数据与该项目的遗传数据整合到毒性，并来自其他R01研究的信息致力于这些队列，例如一系列表型测定。我们假设在标准临床和流行病学变量中添加遗传标记将改善最终风险评估模型的生存和毒性的预测。我们将比较所有患者的预测准确性，仅接受化学疗法的患者和患者通过组合方式处理。该项目产生的风险模型可能使临床医生能够确定在开始治疗之前，患者最有可能受益或发展毒性的患者在为个别患者计划化疗和放疗方面，具有巨大的临床益处。